As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
10 Analysts have issued a NRX Pharmaceuticals Inc forecast:
10 Analysts have issued a NRX Pharmaceuticals Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -14 -14 |
39%
39%
|
EBIT (Operating Income) EBIT | -14 -14 |
39%
39%
|
Net Profit | -34 -34 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
Head office | United States |
CEO | Jonathan Javitt |
Founded | 2017 |
Website | www.nrxpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.